The KCNK3 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated from the A-549 human lung adenocarcinoma epithelial cell line, designed to disrupt the KCNK3 gene encoding the two-pore domain potassium channel TASK-1. This polyclonal population offers a heterogeneous loss-of-function model for investigating the roles of TASK-1 in cellular physiology and disease, avoiding the biases associated with monoclonal isolates. The CRISPR-based gene disruption enables researchers to dissect KCNK3-dependent signaling pathways in a genetically tractable lung cancer background.
The parental A-549 cell line is a widely used model of human lung adenocarcinoma, characterized by adherent growth and retention of key epithelial features. These cells provide a robust platform for cancer biology studies, drug efficacy testing, and electrophysiological investigations due to their well-documented genetic and functional properties. As a KRAS-mutant lung cancer line, A-549 cells recapitulate critical oncogenic pathways, making them particularly suitable for exploring ion channel contributions to tumorigenesis and therapeutic resistance.
KCNK3 (TASK-1) mediates background potassium currents that stabilize the resting membrane potential and regulate cellular excitability. The channel is activated by extracellular alkaline pH and inhibited by acidosis, linking membrane excitability to metabolic and microenvironmental cues. KCNK3 activity is also suppressed by hypoxia and by Gq-coupled receptor stimulation??including serotonin and alpha1-adrenergic receptors??through protein kinase C (PKC) and diacylglycerol signaling. TASK-1 interacts with 14-3-3 proteins, which modulate its surface expression, and its activity converges on downstream effectors such as ERK1/2 and HIF-1??, influencing cell cycle progression, apoptosis, and calcium homeostasis.
In A-549 cells, KCNK3 dysfunction has been associated with altered proliferation and survival, reflecting its role in pulmonary arterial hypertension and lung adenocarcinoma progression. The knockout of KCNK3 in this lung cancer model permits direct assessment of how TASK-1 loss affects oncogenic signaling, hypoxic adaptation, and pharmacological responses. By removing background K+ conductance, the polyclonal knockout cells enable the identification of KCNK3-dependent pathways that contribute to the malignant phenotype and may serve as therapeutic vulnerabilities.
This knockout cell population is suitable for a broad range of applications, including patch-clamp electrophysiology to characterize ion channel properties, cell proliferation and apoptosis assays to evaluate tumor growth, and migration assays to study invasiveness. Researchers can employ RNA-seq or RT-qPCR to profile transcriptional changes upon KCNK3 disruption, or use drug sensitivity testing to identify compounds that exploit KCNK3 loss. The model also supports hypoxia response studies and target validation for pulmonary hypertension. For further information, please contact Ascent Research.
